The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Approximately five kg tumor was removed in the eight-hour long complicated surgery
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
This further adds to Biocon’s portfolio of vertically integrated complex drug products
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The company has has 10 existing labs in India
The funds will be used to scale up existing operations and launch new products
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Subscribe To Our Newsletter & Stay Updated
